Isolation and comparison of mesenchymal stem-like cells from human gastric cancer and adjacent non-cancerous tissues

Xu, Xiaomeng; Zhang, Xu; Wang, Sheng; Qian, Hui; Zhu, Wei; H, Cao; Wang, Mei; Chen, Yuan; Xu, Wenrong

doi:10.1007/s00432-010-0908-6

Cited by 71 publications

(71 citation statements)

References 19 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although this concern has not, thus far, been borne out in human clinical trials, sub-populations of MSC-like cells have been found in the tumour microenvironment of several human cancers including gastric adenocarcinoma [103] and osteosarcoma [104]. Furthermore, some animal model studies have demonstrated preferential migration of intravenously administered MSCs to tumours [105,106].…”

Section: Tumorigenesis and Other Potential Adverse Effects Of Msc-evsmentioning

confidence: 96%

Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications

et al. 2015

View full text Add to dashboard Cite

Mesenchymal stem (stromal) cells (MSCs) are multipotent cells with the ability to differentiate into several cell types, thus serving as a cell reservoir for regenerative medicine. Much of the current interest in therapeutic application of MSCs to various disease settings can be linked to their immunosuppressive and anti-inflammatory properties. One of the key mechanisms of MSC anti-inflammatory effects is the secretion of soluble factors with paracrine actions. Recently it has emerged that the paracrine functions of MSCs could, at least in part, be mediated by extracellular vesicles (EVs). EVs are predominantly released from the endosomal compartment and contain a cargo that includes miRNA, mRNA, and proteins from their cells of origin. Recent animal model-based studies suggest that EVs have significant potential as a novel alternative to whole cell therapies. Compared to their parent cells, EVs may have a superior safety profile and can be safely stored without losing function. In this article, we review current knowledge related to the potential use of MSC-derived EVs in various diseases and discuss the promising future for EVs as an alternative, cell-free therapy.

show abstract

Section: Tumorigenesis and Other Potential Adverse Effects Of Msc-evsmentioning

confidence: 96%

Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications

et al. 2015

View full text Add to dashboard Cite

show abstract

“…BM-MSCs were found to possess the property of spontaneous transformation [93], whereas the Hh pathway was recognized as the key factor for growth and proliferation of these spontaneously transformed MSCs in vivo [94]. MSC-like cells have been isolated from both human GC and adjacent noncancerous tissue [95].…”

Section: Hedgehog Pathwaymentioning

confidence: 99%

“…When bulk cancer cells are diminished by chemotherapy, CSCs are left in awkward situations without necessary nourishment, which may be sufficient for their extinction [133]. In addition, BMDCs and MSC-like cells recently isolated from GC and adjacent noncancerous tissues [95,136] may be the source of carcinoma-associated fibroblasts, which are suspected to promote tumor cell growth, and, along with MSCs, contribute to the CSC niche [137]. An in-depth understanding of in vitro/in vivo crosstalk between different cell types within the tumor milieu may give rise to improved anticancer strategies [137,138].…”

Section: Abc Transportersmentioning

confidence: 99%

Gastric cancer stem cells: therapeutic targets

et al. 2013

View full text Add to dashboard Cite

During the past decade, a growing body of evidence has implied that cancer stem cells (CSCs) play an important role in the development of gastric cancer (GC). The notion that CSCs give rise to GC and may be responsible for invasion, metastasis, and resistance to treatment has profound implications for anti-cancer therapy. Recent major advances in the rapidly evolving field of CSCs have opened novel exciting opportunities for developing CSC-targeted therapies. Discovery of specific markers and signaling pathways in gastric CSCs (GCSCs), with the perfecting of technologies for identification, isolation, and validation of CSCs, may provide the basis for a revolutionary cancer treatment approach based on the eradication of GCSCs. Emerging therapeutic tools based on specific properties and functions of CSCs, including activation of self-renewal signaling pathways, differences in gene expression profiles, and increased activity of telomerase or chemoresistance mechanisms, are developing in parallel with advances in nanotechnology and bioengineering. The addition of GCSC-targeted therapies to current oncological protocols and their complementary application may be the key to successfully fighting GC.

show abstract

“…MSC-like cells can be isolated from tumors such as bone sarcomas, lipomas, and gastric cancers [21][22][23][24] . The characteristics of these MSC-like cells, with respect to morphology, gene expression, surface antigen expression, and differentiation potential, are similar to those of BM-derived MSCs (BM-MSCs).…”

Section: Introductionmentioning

confidence: 99%

Bone Marrow-Derived Mesenchymal Stem Cells Regulate Epithelial-Mesenchymal Transitions and Gastric Cancer Stem Cells

Aoyagi

Kizaki

Isobe

et al. 2017

Journal of Gastroenterology and Hepatology Research

View full text Add to dashboard Cite

from MSCs. Direct contact between BM-derived MSCs (BMMSCs) and gastric cancer cells in vitro increases the proportion of CD133-positive gastric cancer cells. This mechanism is thought to involve stimulation of Wnt-5a and transforming growth factor (TGF)-β by BM-BMCs, directly affecting the gastric cancer cells. Moreover, direct contact between BM-MSCs and gastric cancer cells increases the expression of vimentin and Snail, which is a transcription factor that mediates epithelial-mesenchymal transitions (EMT). Human BM-MSCs can enhance the proliferation, invasion, and chemoresistance of gastric cancer cells. The regulatory mechanism involved is likely associated with increased expression of stem cell markers and EMT-related factors in gastric cancer cells. CD271, which is a marker of BM-MSCs, is expressed in scirrhous carcinoma, and the expression of Wnt-5a and TGF-β in cancer cells is up-regulated. BM-MSCs provide an advantageous tumor microenvironment for gastric cancer. Moreover, BM-MSC-related molecules may be considered biomarkers of gastric cancer. INTRODUCTIONDuring tumor progression, epithelial-mesenchymal transitions (EMT) contribute considerably to the malignant characteristics of tumors, including local invasion and distant metastasis [1,2] . EMT is the key phenomenon that tightly regulates the stem cell-like characteristics of both normal and malignant cells [3,4] . Since cancer stem cells (CSCs) in solid cancers were first identified in the early half of the 2000s, ABSTRACTTumorigenesis is driven by alterations in tumor cells and also changes in the stromal microenvironment. Mesenchymal stem cells (MSCs) are promising candidates for the treatment of various tumors. MSCs are unlikely to be rejected by the immune system, could potentially home to the tumor site, and may interact with tumor cells to influence their growth and metastasis. Using mouse models of inflammationinduced gastric cancer, at least 20% of cancer-associated fibroblasts were found to originate from bone marrow (BM) and were derived REVIEW

show abstract

Isolation and comparison of mesenchymal stem-like cells from human gastric cancer and adjacent non-cancerous tissues

Abstract: Our findings suggest that MSC-like cells are components of the tumor microenvironment and provide proof for the origin of carcinoma-associated fibroblast, therefore may potentially be used as a target for gastric cancer diagnosis and therapy.

Cited by 71 publications

References 19 publications

Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications

Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications

Gastric cancer stem cells: therapeutic targets

Bone Marrow-Derived Mesenchymal Stem Cells Regulate Epithelial-Mesenchymal Transitions and Gastric Cancer Stem Cells

Contact Info

Product

Resources

About